Core Insights - The company reported an 8% organic sales growth in the first nine months, with strong profitability and cash flow, achieving a 37.3% adjusted EBITDA margin despite currency challenges [1][4] - For the fourth quarter, the company anticipates mid-single-digit organic sales growth and has raised its full-year organic sales growth expectation to 7-8% [1][4] - The company continues to execute its strategic priorities effectively, aiming to meet its 2030 targets [1] Sales Performance - Organic sales growth was 8%, with a Q3 growth of 6%, impacted by exiting certain countries by approximately 1 percentage point [4] - Food & Health segment achieved 9% organic sales growth, while Planetary Health recorded 8% [4] - Emerging Markets saw a 12% organic sales growth, compared to 6% in Developed Markets [4] Financial Metrics - Adjusted EBITDA margin improved to 37.3%, up by 130 basis points from Q3 [4] - Adjusted net profit increased by 22%, with a net debt to EBITDA ratio of 2.0x [4] - Free cash flow before acquisitions was EUR 668.4 million, significantly higher than EUR 361.3 million in Q3 [4] Future Outlook - The company now expects organic sales growth for 2025 to be between 7-8%, previously estimated at 6-8% [4] - Excluding the impact of exiting certain countries, the organic sales growth for the year is projected at 8-9% [4] - The adjusted EBITDA margin is anticipated to be at the lower end of the 37-38% range, factoring in currency headwinds [4]

Core Insights - The company reported a strong organic sales growth of 9% in the first half of the year, with an upward revision of the full-year guidance to a range of 6-8% [1][3] - Profitability remains solid despite currency headwinds, with an adjusted EBITDA margin of 37.4%, up by 210 basis points compared to the previous quarter [3] - The company achieved cost synergies at a 100% run rate, indicating improved operational efficiency [3] Sales Performance - Organic sales growth in the Food & Health segment reached 10%, while the Planetary Health segment saw a growth of 9% [3] - Emerging markets experienced a robust organic sales growth of 12%, compared to 8% in developed markets [3] Financial Metrics - Adjusted net profit increased by 23%, reflecting strong financial performance [3] - The company maintained a net interest-bearing debt to EBITDA ratio of 2.1x, following the acquisition of dsm-firmenich's part of the Feed Enzyme Alliance [3] Shareholder Returns - A share buyback program worth EUR 100 million was completed on June 27, enhancing shareholder value [3] - An interim dividend of 2.25 DKK (EUR 0.30) was approved for the first half of 2025 [3] Future Outlook - The company has narrowed its 2025 organic sales growth outlook to 6-8%, with a range of 7-9% excluding exits from certain countries [3] - Long-term financial targets for 2030 have been announced, indicating a strategic focus on growth and investment in unique biosolutions [1][3]